Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury

Molecules

Volumn 15, Issue 9, 2010, Pages 6598-6618

  Thornton, Emma ^a   Ziebell, Jenna M ^a   Leonard, Anna V ^a   Vink, Robert ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Brain injury; Kinins; Neuropeptides; Neurotrauma; Stroke

Indexed keywords

BRADYKININ RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROPROTECTIVE AGENT;

CENTRAL NERVOUS SYSTEM; DRUG ANTAGONISM; EDEMA; HUMAN; INFLAMMATION; INJURY; PATHOLOGY; REVIEW; STROKE;

CENTRAL NERVOUS SYSTEM; EDEMA; HUMANS; INFLAMMATION; NEUROPROTECTIVE AGENTS; RECEPTORS, BRADYKININ; RECEPTORS, NEUROKININ-1; STROKE;

EID: 77957314877     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15096598     Document Type: Review

References (116)

1. Vink, R.; Nimmo, A. J. Multifunctional drugs for head injury. Neurotherapeutics 2009, 6, 28-42.
2. Leeb-Lundberg, L. M.; Marceau, F.; Muller-Esterl, W.; Pettibone, D. J.; Zuraw, B. L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 2005, 57, 27-77.
3. Nimmo, A. J.; Vink, R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat CNS Drug Discov. 2009, 4, 86-95.
4. Raidoo, D. M.; Bhoola, K. D. Pathophysiology of the kallikrein-kinin system in mammalian nervous tissue. Pharmacol. Ther. 1998, 79, 105-127.
5. Rodi, D.; Couture, R.; Ongali, B.; Simonato, M. Targeting kinin receptors for the treatment of neurological diseases. Curr. Pharm. Design 2005, 11, 1313-1326.
6. Hokfelt, T.; Pernow, B.; Wahren, J. Substance P: a pioneer amongst neuropeptides. J. Int. Med. 2001, 249, 27-40.
7. Gerard, N. P.; Garraway, L. A.; Eddy, J. R. L.; Shows, T. B.; Iijima, H.; Paquet, J.-L.; Gerard, C. Human substance P receptor (NK-1): Organisation of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry 1991, 30, 10640-10646.
8. Khawaja, A. M.; Rogers, D. F. Tachykinins: receptor to effector. Int. J. Biochem. Cell Biol. 1996, 28, 721-738.
9. Severini, C.; Improta, G.; Falconieri-Erspamer, G.; Salvadori, S.; Erspamer, V. The tachykinin peptide family. Pharmacol. Rev. 2002, 54, 385-322.
10. Harrison, S.; Geppetti, P. Review: Substance P. Int. J. Biochem. Cell Biol. 2001, 33, 555-576.
11. Pinto, F. M.; Almeida, T. A.; Hernandez, M.; Devillier, P.; Advenier, C.; Candenas, M. L. mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur. J. Pharmacol. 2004, 494, 233-239.
12. Mantyh, P. W.; Johnson, D. J.; Boehmer, C. G.; Catton, M. D.; Vinters, H. V.; Maggio, J. E.; Too, H. P.; Vigna, S. R. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc. Natl. Acad. Sci. USA 1989, 86, 5193-5197.
13. Noda, M.; Kariura, Y.; Pannasch, U.; Nishikawa, K.; Wang, L.; Seike, T.; Ifuku, M.; Kosai, Y.; Wang, B.; Nolte, C.; Aoki, S.; Kettenmann, H.; Wada, K. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J. Neurochem. 2007, 101, 397-410.
14. Rasley, A.; Bost, K. L.; Olson, J. K.; Miller, S. D.; Marriott, I. Expression of functional NK-1 receptors in murine microglia. Glia 2002, 37, 258-267.
15. Stumm, R.; Culmsee, C.; Schafer, M. K.; Krieglstein, J.; Weihe, E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J. Neurosci. 2001, 21, 798-811.
16. Gerard, N. P.; Garraway, L. A.; Eddy, R. L., Jr.; Shows, T. B.; Iijima, H.; Paquet, J. L.; Gerard, C. Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry 1991, 30, 10640-10646.
17. 1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 1999, 375, 51-60.
18. Walker, K.; Perkins, M.; Dray, A. Kinins and kinin receptors in the nervous system. Neurochem. Int. 1995, 26, 1-16.
19. Francel, P. C. Bradykinin and neuronal injury. J. Neurotrauma 1992, 9, S27-S45.
20. Rapoport, R. M.; Murad, F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ. Res. 1983, 52, 352-357. (Pubitemid 13158751)
21. Zausinger, S.; Lumenta, D. B.; Pruneau, D.; Schmid-Elsaesser, R.; Plesnila, N.; Baethmann, A. Effects of LF 16-0687 Ms, a bradykinin B (2) receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia. Brain Res. 2002, 950, 268-278.
22. Mosley, R. L.; Benner, E. J.; Kadiu, I.; Thomas, M.; Boska, M. D.; Hasan, K.; Laurie, C.; Gendelman, H. E. Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin. Neurosci. Res. 2006, 6, 261-281.
23. Rock, R. B.; Peterson, P. K. Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J. Neuroimmune Pharmacol. 2006, 1, 117-126.
24. Torreilles, F.; Salman-Tabcheh, S.; Guerin, M.; Torreilles, J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res. Brain Res. Rev. 1999, 30, 153-163.
25. Brahmachari, S.; Fung, Y. K.; Pahan, K. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J. Neurosci. 2006, 26, 4930-4939.
26. Chauhan, V. S.; Sterka, D. G., Jr.; Gray, D. L.; Bost, K. L.; Marriott, I. Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J. Immunol. 2008, 180, 8241-8249.
27. Guo, C. J.; Douglas, S. D.; Gao, Z.; Wolf, B. A.; Grinspan, J.; Lai, J. P.; Riedel, E.; Ho, W. Z. Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia 2004, 48, 259-266.
28. Parpura, V.; Basarsky, T. A.; Liu, F.; Jeftinija, K.; Jeftinija, S.; Haydon, P. G. Glutamate-mediated astrocyte-neuron signalling. Nature 1994, 369, 744-747.
29. Vink, R.; Young, A.; Bennett, C. J.; Hu, X.; Connor, C. O.; Cernak, I.; Nimmo, A. J. Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. Acta Neurochir. Suppl. 2003, 86, 257-260.
30. Baluk, P.; Bowden, J. J.; Lefevre, P. M.; McDonald, D. M. Upregulation of substance P receptor in angiogenesis associated with chronic airway inflammation in rats. Am. J. Physiol. 1997, 27, L567-L571.
31. Woie, K.; Koller, M. E.; Heyeraas, K. J.; Reed, R. K. Neurogenic inflammation in rat trachea is accompanied by increased negativity of interstitial fluid pressure. Circ. Res. 1993, 73, 839-845. (Pubitemid 23306129)
32. 1 receptors by rat spinal neurons. J. Neurosci. 2003, 23, 1816-1824.
33. Alves, R. V.; Campos, M. M.; Santos, A. R. S.; Calixto, J. B. Receptor subtypes involved in tachykinin-mediated edema formation. Peptides 1999, 20, 921-927.
34. Beck, K. D.; Nguyen, H. X.; Galvan, M. D.; Salazar, D. L.; Woodruff, T. M.; Anderson, A. J. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 2010, 133, 433-447.
35. Prommer, E. Aprepitant (EMEND): the role of substance P in nausea and vomiting. J. Pain Palliative Care Pharmacother. 2005, 19, 31-39.
36. Stewart, J. M.; Gera, L.; York, E. J.; Chan, D. C.; Bunn, P. Bradykinin antagonists: present progress and future prospects. Immunopharmacology 1999, 43, 155-161.
37. Lopes, P.; Kar, S.; Chretien, L.; Regoli, D.; Quirion, R.; Couture, R. Quantitative autoradiographic localization of [125I-Tyr8]bradykinin receptor binding sites in the rat spinal cord: effects of neonatal capsaicin, noradrenergic deafferentation, dorsal rhizotomy and peripheral axotomy. Neuroscience 1995, 68, 867-881.
38. Murone, C.; Paxinos, G.; McKinley, M. J.; Oldfield, B. J.; Muller-Esterl, W.; Mendelsohn, F. A.; Chai, S. Y. Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography. J. Comp. Neurol. 1997, 381, 203-218.
39. Steranka, L. R.; Manning, D. C.; De Haas, C. J.; Ferkany, J. W.; Borosky, S. A.; Connor, J. R.; Vavrek, R. J.; Stewart, J. M.; Snyder, S. H. Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc. Natl. Acad. Sci. USA 1988, 85, 3245-3249.
40. Ziebell, J. M.; Morganti-Kossmann, M. C. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010, 7, 22-30.
41. Stover, J. F.; Dohse, N. K.; Unterberg, A. W. Significant reduction in brain swelling by administration of nonpeptide kinin B2 receptor antagonist LF 16-0687Ms after controlled cortical impact injury in rats. J. Neurosurg. 2000, 92, 853-859.
42. Jeftinija, S. D.; Jeftinija, K. V.; Stefanovic, G.; Liu, F. Neuroligand-evoked calcium-dependent release of excitatory amino acids from cultured astrocytes. J. Neurochem. 1996, 66, 676-684.
43. Rosenblum, W. I. Endothelial dependent relaxation demonstrated in vivo in cerebral arterioles. Stroke 1986, 17, 494-497.
44. Trabold, R.; Eros, C.; Zweckberger, K.; Relton, J.; Beck, H.; Nussberger, J.; Muller-Esterl, W.; Bader, M.; Whalley, E.; Plesnila, N. The role of bradykinin B (1) and B (2) receptors for secondary brain damage after traumatic brain injury in mice. J. Cerebr. Blood Flow Metabol. 2009, 30, 130-139.
45. Ongali, B.; Hellal, F.; Rodi, D.; Plotkine, M.; Marchand-Verrecchia, C.; Pruneau, D.; Couture, R. Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier. J. Neurotrauma 2006, 23, 696-707.
46. Hellal, F.; Pruneau, D.; Palmier, B.; Faye, P.; Croci, N.; Plotkine, M.; Marchand-Verrecchia, C. Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J. Neurotrauma 2003, 20, 841-851.
47. Raslan, F.; Schwarz, T.; Meuth, S. G.; Austinat, M.; Bader, M.; Renne, T.; Roosen, K.; Stoll, G.; Siren, A. L.; Kleinschnitz, C. Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J. Cerebr. Blood Flow Metabol. 2010, 30, 1477-1486.
48. Unterberg, A.; Dautermann, C.; Baethmann, A.; Muller-Esterl, W. The kallikrein-kinin system as mediator in vasogenic brain edema. Part 3: Inhibition of the kallikrein-kinin system in traumatic brain swelling. J. Neurosurg. 1986, 64, 269-276.
49. Auer, L. M.; Marth, E.; Heppner, F.; Holasek, A. Proteolytic enzyme activity in patients with severe head injury and the effect of a proteinase inhibitor. Acta Neurochir. (Wien) 1979, 49, 207-217.
50. Pruneau, D.; Chorny, I.; Benkovitz, V.; Artru, A.; Roitblat, L.; Shapira, Y. Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma. J. Neurotrauma 1999, 16, 1057-1065.
51. Schulz, J.; Plesnila, N.; Eriskat, J.; Stoffel, M.; Pruneau, D.; Baethmann, A. LF 16-0687 a novel non-peptide bradykinin B2 receptor antagonist reduces vasogenic brain edema from a focal lesion in rats. Acta Neurochir. Suppl. 2000, 76, 137-139.
52. Plesnila, N.; Schulz, J.; Stoffel, M.; Eriskat, J.; Pruneau, D.; Baethmann, A. Role of bradykinin B2 receptors in the formation of vasogenic brain edema in rats. J. Neurotrauma 2001, 18, 1049-1058.
53. Marmarou, A.; Guy, M.; Murphey, L.; Roy, F.; Layani, L.; Combal, J. P.; Marquer, C. A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J. Neurotrauma 2005, 22, 1444-1455.
54. Shakur, H.; Andrews, P.; Asser, T.; Balica, L.; Boeriu, C.; Quintero, J. D.; Dewan, Y.; Druwe, P.; Fletcher, O.; Frost, C.; Hartzenberg, B.; Mantilla, J. M.; Murillo-Cabezas, F.; Pachl, J.; Ravi, R. R.; Ratsep, I.; Sampaio, C.; Singh, M.; Svoboda, P.; Roberts, I. The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009, 10, 109.
55. Simmon, V. F. Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009, 10, 110.
56. Marmarou, A.; Nichols, J.; Burgess, J.; Newell, D.; Troha, J.; Burnham, D.; Pitts, L. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J. Neurotrauma 1999, 16, 431-444.
57. Ker, K.; Blackhall, K. Beta-2 receptor antagonists for acute traumatic brain injury. Cochrane Database Syst. Rev. 2008, CD006686.
58. Donkin, J. J.; Nimmo, A. J.; Cernak, I.; Blumbergs, P. C.; Vink, R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J. Cerebr. Blood Flow Metabol. 2009, 29, 1388-1398.
59. Donkin, J. J.; Vink, R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr. Opin. Neurol. 2010, 23, 293-299.
60. Zacest, A. C.; Vink, R.; Manavis, J.; Sarvestani, G. T.; Blumbergs, P. C. Substance P immunoreactivity increases following human traumatic brain injury. Acta Neurochir. Suppl. 2010, 106, 211-216.
61. Williams, T. A.; Hooper, N. M.; Turner, A. J. Characterization of neuronal and endothelial forms of angiotensin converting enzyme in pig brain. J. Neurochem. 1991, 57, 193-199.
62. Harford-Wright, E.; Thornton, E.; Vink, R. Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci. Lett. 2010, 481, 26-29.
63. Nimmo, A. J.; Cernak, I.; Heath, D. L.; Hu, X.; Bennett, C. J.; Vink, R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 2004, 38, 40-47.
64. Vink, R.; Donkin, J. J.; Cruz, M. I.; Nimmo, A. J.; Cernak, I. A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. J. Amer. Coll. Nutr. 2004, 23, 538S-540S.
65. Vink, R.; Cook, N. L.; van den Heuvel, C. Magnesium in acute and chronic brain injury: an update. Magnes. Res. 2009, 22, 158S-162S.
66. Vink, R.; van den Heuvel, C. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 2010, 7, 74-80.
67. Sharma, H. S.; Westman, J. Blood-Spinal Cord and Brain Barriers in Health and Disease; Elsevier Academic Press: San Diego, CA, USA, 2004; pp. 437-518.
68. Brightman, M. W.; Klatzo, I.; Olsson, Y.; Reese, T. S. The blood-brain barrier to proteins under normal and pathological conditions. J. Neurol. Sci. 1970, 10, 215-239.
69. Sharma, H. S. Pathophysiology of blood-spinal cord barrier in traumatic injury and repair. Curr. Pharm. Design 2005, 11, 1353-1389.
70. Popovich, P. G.; Horner, P. J.; Mullin, B. B.; Stokes, B. T. A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp. Neurol. 1996, 142, 258-275.
71. Tian, D. S.; Liu, J. L.; Xie, M. J.; Zhan, Y.; Qu, W. S.; Yu, Z. Y.; Tang, Z. P.; Pan, D. J.; Wang, W. Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats. J. Neurochem. 2009, 109, 1658-1667.
72. Ates, O.; Cayli, S. R.; Gurses, I.; Turkoz, Y.; Tarim, O.; Cakir, C. O.; Kocak, A. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J. Clin. Neurosci. 2007, 14, 658-665.
73. Nesic, O.; Lee, J.; Ye, Z.; Unabia, G. C.; Rafati, D.; Hulsebosch, C. E.; Perez-Polo, J. R. Acute and chronic changes in aquaporin 4 expression after spinal cord injury. Neuroscience 2006, 143, 779-792.
74. Sharma, H. S.; Olsson, Y.; Nyberg, F.; Dey, P. K. Prostaglandins modulate alterations of microvascular permeability, blood flow, edema and serotonin levels following spinal cord injury: an experimental study in the rat. Neuroscience 1993, 57, 443-449.
75. Sharma, H. S.; Winkler, T.; Stalberg, E.; Olsson, Y.; Dey, P. K. Evaluation of traumatic spinal cord edema using evoked potentials recorded from the spinal epidural space. An experimental study in the rat. J. Neurol. Sci. 1991, 102, 150-162.
76. Winkler, T.; Sharma, H. S.; Stalberg, E.; Olsson, Y.; Nyberg, F. Opioid receptors influence spinal cord electrical activity and edema formation following spinal cord injury: experimental observations using naloxone in the rat. Neurosci. Res. 1994, 21, 91-101.
77. Bilgen, M.; Dogan, B.; Narayana, P. A. In vivo assessment of blood-spinal cord barrier permeability: serial dynamic contrast enhanced MRI of spinal cord injury. Magn. Reson. Imaging 2002, 20, 337-341.
78. Cohen, D. M.; Patel, C. B.; Ahobila-Vajjula, P.; Sundberg, L. M.; Chacko, T.; Liu, S. J.; Narayana, P. A. Blood-spinal cord barrier permeability in experimental spinal cord injury: dynamic contrastenhanced MRI. NMR Biomed. 2009, 22, 332-341.
79. Xu, J.; Hsu, C. Y.; Junker, H.; Chao, S.; Hogan, E. L.; Chao, J. Kininogen and kinins in experimental spinal cord injury. J. Neurochem. 1991, 57, 975-980.
80. Pan, W.; Kastin, A. J.; Gera, L.; Stewart, J. M. Bradykinin antagonist decreases early disruption of the blood-spinal cord barrier after spinal cord injury in mice. Neurosci. Lett. 2001, 307, 25-28.
81. Sharma, H. S. A bradykinin BK2 receptor antagonist HOE-140 attenuates blood-spinal cord barrier permeability following a focal trauma to the rat spinal cord. An experimental study using Evans blue, [131]I-sodium and lanthanum tracers. Acta Neurochir. Suppl. 2000, 76, 159-163.
82. McCarthy, D. A.; Potter, D. E.; Nicolaides, E. D. An in vivo estimation of the potencies and halflives of synthetic bradykinin and kallidin. J. Pharmacol. Exp. Ther. 1965, 148, 117-122.
83. Sharma, H. S.; Nyberg, F.; Olsson, Y.; Dey, P. K. Alteration of substance P after trauma to the spinal cord: an experimental study in the rat. Neuroscience 1990, 38, 205-212. (Pubitemid 20334934)
84. Faden, A. I.; Jacobs, T. P.; Holaday, J. W. Opiate antagonist improves neurologic recovery after spinal injury. Science 1981, 211, 493-494.
85. Naftchi, N. E.; Abrahams, S. J.; St Paul, H. M.; Lowman, E. W.; Schlosser, W. Localization and changes of substance P in spinal cord of paraplegic cats. Brain Res. 1978, 153, 507-513.
86. Vita, G.; Haun, C. K.; Hawkins, E. F.; Engel, W. K. Effects of experimental spinal cord transection on substance P receptors: a quantitative autoradiography study. Neuropeptides 1990, 17, 147-153.
87. Faden, A. I.; Jacobs, T. P.; Helke, C. J. Changes in substance P and somatostatin in the spinal cord after traumatic spinal injury in the rat. Neuropeptides 1985, 6, 215-225.
88. Naftchi, N. E. Prevention of damage in acute spinal cord injury by peptides and pharmacologic agents. Peptides 1982, 3, 235-247.
89. Young, W.; Flamm, E. S.; Demopoulos, H. B.; Tomasula, J. J.; De Crescito, V. Effect of naloxone on posttraumatic ischemia in experimental spinal contusion. J. Neurosurg. 1981, 55, 209-219.
90. Moore, S. D.; Madamba, S. G.; Schweitzer, P.; Siggins, G. R. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro. J. Neurosci. 1994, 14, 809-820.
91. Vink, R.; Portoghese, P. S.; Faden, A. I. Kappa-opioid antagonist improves cellular bioenergetics and recovery after traumatic brain injury. Amer. J. Physiol. 1991, 261, R1527-1532.
92. Suarez-Roca, H.; Maixner, W. Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices. J. Pharmacol. Exp. Ther. 1993, 264, 648-653.
93. McCarson, K. E.; Goldstein, B. D. Naloxone blocks the formalin-induced increase of substance P in the dorsal horn. Pain 1989, 38, 339-345.
94. Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Davalos, A.; Guidetti, D.; Larrue, V.; Lees, K. R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von Kummer, R.; Wahlgren, N.; Toni, D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 2008, 359, 1317-1329.
95. Groger, M.; Lebesgue, D.; Pruneau, D.; Relton, J.; Kim, S. W.; Nussberger, J.; Plesnila, N. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J. Cerebr. Blood Flow Metabol. 2005, 25, 978-989.
96. Wagner, S.; Kalb, P.; Lukosava, M.; Hilgenfeldt, U.; Schwaninger, M. Activation of the tissue kallikrein-kinin system in stroke. J. Neurol. Sci. 2002, 202, 75-76.
97. Kamiya, T.; Katayama, Y.; Kashiwagi, F.; Terashi, A. The role of bradykinin in mediating ischemic brain edema in rats. Stroke 1993, 24, 571-575.
98. Austinat, M.; Braeuninger, S.; Pesquero, J. B.; Brede, M.; Bader, M.; Stoll, G.; Renne, T.; Kleinschnitz, C. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 2009, 40, 285-293.
99. Su, J.; Cui, M.; Tang, Y.; Zhou, H.; Liu, L.; Dong, Q. Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem. Biophys. Res. Commun. 2009, 388, 205-211.
100. Relton, J. K.; Beckey, V. E.; Hanson, W. L.; Whalley, E. T. CP-0597, a selective bradykinin B2 receptor antagonist, inhibits brain injury in a rat model of reversible middle cerebral artery occlusion. Stroke 1997, 28, 1430-1436.
101. Zhao, H. Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J. Cerebr. Blood Flow Metabol. 2009, 29, 873-885.
102. Burda, J.; Danielisova, V.; Nemethova, M.; Gottlieb, M.; Matiasova, M.; Domorakova, I.; Mechirova, E.; Ferikova, M.; Salinas, M.; Burda, R. Delayed postconditionig initiates additive mechanism necessary for survival of selectively vulnerable neurons after transient ischemia in rat brain. Cell. Mol. Neurobiol. 2006, 26, 1141-1151.
103. Burda, J.; Matiasova, M.; Gottlieb, M.; Danielisova, V.; Nemethova, M.; Garcia, L.; Salinas, M.; Burda, R. Evidence for a role of second pathophysiological stress in prevention of delayed neuronal death in the hippocampal CA1 region. Neurochem. Res. 2005, 30, 1397-1405.
104. Xia, C. F.; Yin, H.; Borlongan, C. V.; Chao, L.; Chao, J. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 2004, 43, 452-459.
105. Xia, C. F.; Yin, H.; Yao, Y. Y.; Borlongan, C. V.; Chao, L.; Chao, J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene Ther. 2006, 17, 206-219. (Pubitemid 43262036)
106. Kuhr, F.; Lowry, J.; Zhang, Y.; Brovkovych, V.; Skidgel, R. A. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010, 44, 145-154.
107. Danielisova, V.; Gottlieb, M.; Nemethova, M.; Burda, J. Effects of bradykinin postconditioning on endogenous antioxidant enzyme activity after transient forebrain ischemia in rat. Neurochem. Res. 2008, 33, 1057-1064.
108. Xia, C. F.; Smith, R. S., Jr.; Shen, B.; Yang, Z. R.; Borlongan, C. V.; Chao, L.; Chao, J. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 2006, 47, 752-761.
109. Kleinschnitz, C.; Austinat, M.; Bader, M.; Renne, T.; Stoll, G. Deficiency of bradykinin receptor B2 is not detrimental in experimental stroke. Hypertension 2008, 51, e41.
110. Turner, R. J.; Blumbergs, P. C.; Sims, N. R.; Helps, S. C.; Rodgers, K. M.; Vink, R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. Acta Neurochir. Suppl. 2006, 96, 263-266.
111. Bruno, G.; Tega, F.; Bruno, A.; Graf, U.; Corelli, F.; Molfetta, R.; Barucco, M. The role of substance P in cerebral ischemia. Int. J. Immunopathol. Pharmacol. 2003, 16, 67-72.
112. Kim, D. K.; Oh, E. K.; Summers, B. A.; Prabhakar, N. R.; Kumar, G. K. Release of substance P by low oxygen in the rabbit carotid body: evidence for the involvement of calcium channels. Brain Res. 2001, 892, 359-369.
113. Yu, Z.; Cheng, G.; Huang, X.; Li, K.; Cao, X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. Neuroreport 1997, 8, 2117-2119.
114. Turner, R.; Vink, R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Drug News Perspect. 2007, 20, 221-226.
115. Kramer, J. H.; Phillips, T. M.; Weglicki, W. B. Magnesium-deficiency- enhanced post-ischemic myocardial injury is reduced by substance P receptor blockade. J. Mol. Cell. Cardiol. 1997, 29, 97-110.
116. Weglicki, W. B.; Phillips, T. M.; Mak, I. T.; Cassidy, M. M.; Dickens, B. F.; Stafford, R.; Kramer, J. H. Cytokines, neuropeptides and reperfusion injury during magnesium deficiency. Ann. N. Y. Acad. Sci. 1994, 17, 246-257.